Populära just nu
Today, BioInvent announced the initiation of the phase IIa monotherapy part of the study of BI-1808,...
Yesterday, Carasent announced that, following a review of the company’...
SSH Communications Security: Order announcement
Crunchfish has announced a 60% guaranteed SEK 85 million rights issue.
As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expec...
Initiates strategic review to evaluate funding and ownership No timeline; FY'23 guidance unchanged W...
Travere, with its conditionally approved FILSPARI, is the only Tarpeyo...
Innehavet i Studentbostäder tyngde resultatet i Q2 och fokus framåt li...
Redeye endorses the first results from Enzymatica’s ongoing independent clinical study at the Univer...
Redeye shares its takeaways from the Digitalize and Automate 2023 event – focusing on Effie AI and A...
Redeye comments on Optomed’s directed share issue, raising EUR4.
Redeye is positive to the news that Waystream continues to receive ord...
This morning, Vow announced a modification order for a hybrid heating ...
Syncro Group (alt. ”Koncernen”) har tidigare presenterat sin Q2-rapport vilken kom in något svagare ...
Duell released a profit warning ahead of the FY 2023 earnings which will be published 9th of October...
Yesterday, Vertiseit announced the divestment of its transportation business.
Redeye comments on the additional data presented from the phase IIa st...
Redeye comments on the announcement of another collaboration for a bac...
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company i...
Recently (Monday Sep 18), those who had purchased more expensive special editions of Payday 3 were g...
Redeye views favorably on the order received by the subsidiary Citilog to deliver its AI and Deep Le...
Redeye comments on Ortoma’s agreement with DePuy Synthes.
Redeye envisions an exciting period on the horizon for Xspray Pharma f...
Redeye provides a research update following Infracom’s acquisitions of ComCenter.
We have now included acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in our sum-of-...
